Remove Clinical Trials Remove Doctors Remove Genetics Remove In-Vivo
article thumbnail

Gene editing: beyond the hype

pharmaphorum

This has, of course, garnered immense excitement – Doctors Emmanuelle Charpentier and Jennifer Doudna were named winners of the Nobel Prize for chemistry in recognition of their discovery of CRISPR/Cas9 gene editing technology. Zinc fingers. Macrae had previously worked at GSK and Takeda before he was recruited by Sangamo.

article thumbnail

Katie Porter attacks pharma

World of DTC Marketing

I have been recruited by these companies who promise huge payouts when they are acquired if their drug shows promise in clinical trials. Ex vivo (where cells are genetically modified outside the body) cell and gene therapies have generated considerable excitement on their potential to cure previously incurable diseases.

In-Vivo 187
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gulf War Illness: How can disease modelling aid the search for a cure?

pharmaphorum

Thirty years on, GWI has proven itself to be a challenging clinical condition; chronic and multisymptomatic by nature, the disease affects around a third of all veterans who served during the Gulf War. Disease modelling Gulf War Illness. In the mid-to-late 1990s, an unexplained illness began to emerge in army bases across the US.

In-Vivo 98
article thumbnail

The evolution of assays for immuno-oncology research

Drug Discovery World

Genetically modified T cells stimulated with IL2 are now administered as cell therapy for multiple cancer cell types with beneficial results 3,4. Over 250 clinical trials are currently in progress, and novel immuno-oncological treatments are already proving to be successful. This continues to be the standard of care.

article thumbnail

Necessity Is the Mother of Innovation: Key Trends and Predictions from Biotech Showcase Digital After an Unprecedented Year That Drove Momentous Changes in Healthcare

Pharma Marketing Network

In other areas of the industry (such as cell and genetic medicine development) progress continued at an impressively brisk pace despite the pandemic. Regarding OWS’s support for vaccine development, Dr Slaoui noted that 5 of the 6 vaccines selected (from a total of 94 programs) are currently in phase 3 development or approved.

article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

Dr. Lin received a medical degree from Shanghai Medical University and specialized in hematology after which she began working in the clinical research unit at the university, treating patients with acute leukemia. However, this has since changed, and now, transitioning between academia and industry has become more commonplace. Key Moments.